Genmab A/S ADS

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...

The European Commission has approved TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. The Phase 3 EPCORE® FL-1 trial demonstrated that the fixed-duration combination therapy reduced disease progression or death risk by 79% compared to standard care, with 96% overall ...

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% overall response rate and 86% complete response rate with durable rem...

Genmab A/S announced the disclosure of share transactions made by managerial employees and their closely associated persons in accordance with EU market abuse regulations. The company also announced a capital increase of 2,346 shares resulting from employee warrant exercises.

The bispecific antibody drug conjugate (BsADC) market is expected to reach over $2 billion by 2030, with the first BsADC approval anticipated by 2028. Over 150 clinical trials are underway globally, with China leading development efforts. Key candidates like Izalontamab brengitecan and JSKN003 are showing positive clinical results in cancer treat...